Precision medicine: an intrahepatic cholangiocarcinoma with a novel RBPMS-MET fusion sensitive to crizotinib.

Autor:	Wan W; Department of Medical Oncology, Xi'an International Medical Center, Shaanxi, Xi'an, 710100, People's Republic of China., Liu X; Department of Medical Oncology, Xi'an International Medical Center, Shaanxi, Xi'an, 710100, People's Republic of China., Zhang Y; Department of Medical Oncology, Xi'an International Medical Center, Shaanxi, Xi'an, 710100, People's Republic of China., Shen R; Department of Medical Oncology, Xi'an International Medical Center, Shaanxi, Xi'an, 710100, People's Republic of China., Xia W; Department of Medical Oncology, Xi'an International Medical Center, Shaanxi, Xi'an, 710100, People's Republic of China., Li S; Department of Gastroenterology, Xi'an International Medical Center, Shaanxi, Xi'an, 710100, People's Republic of China., Tan Y; The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, 210018, People's Republic of China., Duan Q; The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, 210018, People's Republic of China., Liu J; Department of Medical Oncology, Xi'an International Medical Center, Shaanxi, Xi'an, 710100, People's Republic of China., Wang W; Department of Thoracic Surgery, Xi'an International Medical Center, Shaanxi, Xi'an, 710100, People's Republic of China.
Jazyk:	angličtina
Zdroj:	The oncologist [Oncologist] 2024 Dec 10. Date of Electronic Publication: 2024 Dec 10.
DOI:	10.1093/oncolo/oyae340
Abstrakt:	Background: Intrahepatic cholangiocarcinoma is a malignant tumor that starts from the epithelium of the bile duct and has a poor prognosis. They are characterized by poor response to chemotherapy and lack of effective targeted therapies; thus, therapeutic options are limited. Case Presentation: A 59-year-old man was admitted to the hospital for a workup of abnormal CA19-9 levels. He was diagnosed with ICC, underwent surgery and was found to have pT1bNx disease. He developed rapid disease recurrence on adjuvant gemcitabine + capecitabine. Following recurrence, he received first-line systemic pembrolizumab + lenvatinib and second-line pembrolizumab + lenvatinib + chemotherapy and had mild tumor regression followed by progression. Next-generation sequencing was performed on the baseline surgical sample. This revealed a novel RBPMS-MET fusion, and based on the literature, crizotinib 250 mg twice a day was administered. After 3 months of crizotinib treatment, magnetic resonance imaging revealed a significant reduction in liver lesions, and 4 months after initiating treatment, scans demonstrated a partial response. Conclusion: Our case report strengthens the evidence that crizotinib may be a viable treatment option for patients with ICC with a c-MET tyrosine kinase fusion, necessitating additional clinical investigation. (© The Author(s) 2024. Published by Oxford University Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu